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 INTRODUCTION 
 Infl ammatory bowel disease (IBD) comprises a group of disorders 
characterized by chronic intestinal infl ammation with the 
main phenotypes being Crohn ’ s disease (CD) and ulcera-
tive colitis (UC). Th e incidence of IBD is rising, especially in 
children ( 1 – 3 ). Genetic discoveries implicate intracellular 
bacterial recognition (NOD2) and mechanisms of intracellu-
lar bacterial handling such as autophagy ( 4,5 ). Th e importance 
of the host innate immune response to bacteria highlighted 
by these discoveries has resulted in a renewed interest in the 
intestinal microbiota in IBD. Th e microbiota fulfi lls important 
roles in immunological development, defense against pathogens, 
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The majority of studies to date are however potentially confounded by the effect of treatment and a 
reliance on established rather than  de-novo disease. 
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bacteria,  P  =  0.02). No disease-specifi c clustering was evident on principal components analysis. 
 CONCLUSIONS:  Our results offer a comprehensive examination of the IBD mucosal microbiota at diagnosis, 
unaffected by therapeutic confounders or changes over time. Our results challenge the current model 
of a protective role for  F. prausnitzii in CD, suggesting a more dynamic role for this organism than 
previously described. 
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production of exogenous enzymes, and salvage of dietary energy 
( 6,7 ). Studies on the microbiota of IBD have revealed changes 
in its composition, which are now part of the disease pathogen-
esis paradigm. Th ese include an increase in bacterial numbers, a 
reduction in bacterial diversity, increases in the phyla Proteobac-
teria and Bacteroidetes, and a reduction in Firmicutes ( 8 – 11 ). 
Th e published evidence to date has relied on largely opportun-
istic studies of patients with established disease, providing a 
microbial snapshot of the chronic disease state at various time 
points aft er diagnosis. A signifi cant limitation of this approach 
however is that the major confounders of active treatment and 
disease chronicity make it impossible to interpret events follow-
ing on from disease initiation ( 12 ). Th e interrogation of the fecal 
microbiota in many studies also introduces a diffi  culty, as the 
mucosal and fecal bacterial ecosystems are recognized as being 
distinct in health, but with little known in disease states ( 13,14 ). 
 Pediatric IBD off ers an opportunity to explore these problems, 
since children are relatively free of additional signifi cant co-
morbidities and are generally treatment na ï ve at IBD diagnosis. 
For these reasons, we set up the  “ Bacteria in Infl ammatory bowel 
disease in Scottish Children Undergoing Investigation before 
Treatment ” (BISCUIT) study. 
 METHODS 
 Patient recruitment, biopsy collection, and processing 
 Patients were recruited to the BISCUIT study from routine 
colonoscopy lists in each of three pediatric centers (Royal Aber-
deen Children ’ s Hospital, Aberdeen; Royal Hospital for Sick 
Children, Glasgow; and Ninewells Hospital, Dundee). An ini-
tial approach with study information was made either by post in 
advance of admission or on the day of admission, a minimum of 
12  h in advance of the procedure. Patients under investigation in 
the pediatric centers were approached if the attending clinician 
deemed it possible that they would be found to have either IBD or 
a normal colon at colonoscopy. Patients were excluded if they had 
received systemic antibiotics or steroids in the 3 months before 
their colonoscopy or immunosuppression at any time, or if they 
had a previous diagnosis of IBD. All patients were investigated as 
per the Porto criteria, then diagnosed and phenotyped with refer-
ence to standard criteria ( 15 – 18 ). 
 Over 3 years the study recruited 100 children undergoing colon-
oscopy throughout Scotland in two categories, those with likely IBD, 
at fi rst presentation, with macroscopic colonic infl ammation ( n  =  45) 
and those undergoing colonoscopy who subsequently had a normal 
colon macroscopically ( n  =  55). Th e fi nal IBD cohort comprised 44 
confi rmed IBD subjects (29 CD, 13 UC, and 2 IBD, type unclassi-
fi ed). Th e remaining  “ likely IBD ” (infl amed colon) subject had mild, 
non-specifi c chronic infl ammation in their distal colon on histopa-
thology. Th is was insuffi  cient to warrant a formal IBD diagnosis. 
 Biopsies were taken from a single site, from the distal colon in con-
trols (rectum / sigmoid), or from the most distal infl amed site in IBD. 
In all, 2 – 3 biopsies were collected using standard endoscopic forceps. 
Biopsies were collected into a sterile 1.5  ml Eppendorf container and 
placed immediately onto ice before transfer to   −  80  ° C storage. 
 To explore bacterial diversity, 37 subjects were identifi ed for 
further analysis ( Table 1 ;  Supplementary Table 1 ). Twelve UC 
were included, all with distal colonic infl ammation. Th irteen 
CD patients were identifi ed with granulomatous change in their 
biopsy set, fi rmly supportive of their diagnosis, and distal colonic 
infl ammation in keeping with CD (and hence distal colonic 
biopsies) to match colonic site with the control and UC cohorts. 
Twelve controls were selected as most representative of  “ normal, ” 
having both a macroscopically  and a microscopically normal 
colon, matched as closely as possible for age and sex to the IBD 
groups. None of the controls have gone on to develop IBD with a 
mean time since endoscopy of 23 months (minimum 7 months). 
 DNA extraction of mucosal biopsies was performed using the com-
mercially available Qiagen QIAamp Mini kit (Qiagen, Crawley, UK) 
with minor modifi cations ( 19 ). A test PCR was performed as described 
previously with biopsy DNA utilizing primers universal for bacteria to 
confi rm the suitability of the DNA for further analysis ( 20 ). 
 Ethical approval was granted by North of Scotland Research 
Ethics Service (09 / S0802 / 24) on behalf of all participating centers 
and written informed consent was obtained from the parents of all 
subjects. Informed assent was also obtained from older children who 
were deemed capable of understanding the nature of the study. 
 Th is study is publicly registered on the United Kingdom Clinical 
Research Network Portfolio (9633). 
 Preparation of samples for pyrosequencing 
 Biopsy DNA was quantifi ed by Nanodrop mass spectrophotometry 
before dilution to 25  ng / μ l. Initial PCR amplifi cation was under-
taken with FastStart High Fidelity PCR reagents (Roche, Penzberg, 
Germany) utilizing a per-reaction mix of 50  ng of DNA template, 
10 × FastStart High Fidelity Reaction Buff er with 90  nM MgCl 2 , 
10  nM dNTPs, 10  pM Fusion Primer A, 10  pM Fusion Primer B, 
5  U FastStart High Fidelity Enzyme Blend. Th e 16S rDNA prim-
ers were taken from Dethlefsen  et al. ( 21 ); however, we utilized 
the 338f partnered with 1064r, spanning the V3 – V6 region of the 
16S rRNA gene and providing a  ~ 726-bp product. For the forward 
primer, two multiplex identifi ers (MID1 and MID2) were used to 
allow multiplexing of paired samples during sequencing. No iden-
tifi er was added to the reverse primer. Hence, the  ~ 726-bp PCR 
product was fl anked by a 40-bp fusion primer / multiplex identifi er 
sequence at the forward end and a 30-bp fusion primer at the reverse 
end therefore resulting in a  ~ 796-bp sequence. Th e fi nal primers 
were A-338f1 5 ′ - CCATCTCATCCCTGCGTGTCTCCGACTC
AG ACGAGTGCGT ACTCCTACGGGAGGCAGCAG-3 ′ ; A-338f2 
5 ′ - CCATCTCATCCCTGCGTGTCTCCGACTCAG ACGCTCG
ACA ACTCCTACGGGAGGCAGCAG-3 ′ and B-1064r 5 ′ - CCTAT
CCCCTGTGTGCCTTGGCAGTCTCAG CGACARCCATG
CASCACCT-3 ′ (page-purifi ed primers by Sigma-Aldrich, Gilling-
ham, UK) with the bold sections corresponding to fusion primers, 
the underlined sections multiplex identifi ers, and the standard text 
to the 16S primers. 
 PCR cycling conditions were taken from the modifi ed condi-
tions of Dethlefsen and were briefl y as follows: 3  min at 94  ° C; 30 
cycles of 30  s at 94  ° C, 45  s at 55  ° C, 60  s at 72  ° C; 2  min at 72  ° C ( 21 ). 
Aft er confi rmation of successful PCR amplifi cation, products were 
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purifi ed as per the recommended Agencourt AMPure (Beckman 
Coulter, Beverly, MA) purifi cation method for 454 sequencing and 
sequenced on Roche 454 Titanium (454 Life Sciences, Branford, 
CT) by NewGene (Newcastle, UK). 
 Real-time PCR 
 Quantitative real-time PCR (RT-PCR) was performed as described 
previously ( 22 ). Briefl y, standard curves consisted of 10-fold dilu-
tion series of amplifi ed bacterial 16S rRNA genes from reference 
strains. Samples were amplifi ed with universal primers against 
total bacteria and specifi c primers against  Bacteroidetes , Firmi-
cutes clostridial cluster IV, Firmicutes clostridial cluster XIVa, 
 Enterobacteriaceae and  Faecalibacterium prausnitzii ( Table 2 ). 
 Supplementary methods 
 Supplementary Methods contain additional detail on RT-PCR 
methodology, bioinformatic analysis of pyrosequencing data, and 
statistical analyses. 
 RESULTS 
 Pyrosequencing generated >1 million individual sequencing 
reads in total with a mean yield of 21,691 reads per subject 
after bioinformatic processing but before rarefaction ( Supple-
mentary Table 2 ). Of the 37 subjects in the study, 2 did not 
meet the 10,000 read threshold and were excluded, 1 UC whose 
bacterial DNA amplified poorly and failed quality control for 
pyrosequencing and 1 CD who was sequenced as all other sub-
jects, but who only yielded 739 reads. In all, 1 further subject 
(CD) was sequenced and rarefied alongside the final 34, but 
99.9 % of their 11,000 reads were unmatched at phylum level. 
Thus, 34 subjects were ultimately represented by 11,000 rar-
efied reads after bioinformatic processing, allowing subject-
to-subject comparison. The only resultant demographic change 
was a loss of significance in symptom duration between CD 
and controls ( Table 1 ). 
 In all, 1 UC subject amplifi ed poorly by RT-PCR despite suc-
cessful pyrosequencing of their sample yielding 24,240 reads. A 
further attempt at RT-PCR with 50  ng DNA template was also 
unsuccessful; therefore, this subject was not included in RT-PCR 
correlations ( n  =  33) but  was included in pyrosequencing analy-
ses ( n  =  34). Pyrosequencing fi ndings correlated with RT-PCR 
results to a 0.01 signifi cance level (Pearson coeffi  cients: Bacteroi-
detes 0.624 ( n  =  33), Firmicutes 0.571 ( n  =  33), Proteobacteria 
0.891 ( n  =  20, restricted to those where Proteobacteria were above 
RT-PCR detection threshold)). 
 Table 1 .  Statistical comparisons of study group demographics of original and fi nal cohort 
 Original cohort 
 Controls ( n =12)  
 M edian (Min to 
Max) 
 Crohn’s ( n =13)  
 M edian (Min to 
Max) 
 UC ( n =12)  
 M edian (Min to 
Max) 
 All ( n =37)  
 M edian (Min to 
Max) 
 Statistical comparison (Mann – Whitney  U test unless 
indicated) 
      Control vs. Crohn’s  Control vs. UC  Crohn’s vs. UC 
 Age  11.4 (6.3 to 15.3)  12.2 (8.0 to 16.3)  13.0 (8.5 to 15.8)  12.2 (6.3 to 16.3)  0.140  0.424  0.533 
 Male:female  8:4  10:3  9:3  27:10  0.673 a  1.00 a  1.00 a 
 Height Z-score  0.1 (  −  0.4 to 2.1)   −  0.7 (  −  2.5 to 1.9)  0.3 (  −  1.7 to 2.8)  0.1 (  −  2.5 to 2.8)  0.176  0.902  0.279 
 Weight Z-score  1.1 (  −  0.7 to 2.3)   −  1.1 (  −  2.5 to 2.6)  0.0 (  −  1.6 to 1.8)  0.1 (  −  2.5 to 2.6)  0.023  0.049  0.140 
 BMI Z-score  1.1 (  −  0.7 to 2.2)   −  0.9 (  −  3.7 to 2.8)   −  0.1 (  −  2.2 to 1.7)  0.3 (  −  3.7 to 2.8)  0.007  0.031  0.622 
 Symptom 
duration 
(months) 
 12 (0 b to 36)  6 (1.5 to 21)  4.5 (0.5 to 36)  7 (0 to 36)  0.044  0.060  0.429 
 Final cohort  Controls ( n =12)  
 M edian (Min to 
Max) 
 Crohn’s ( n =11)  
 M edian (Min to 
Max) 
 UC ( n =11)  
 M edian (Min to 
Max) 
 All ( n =34)  
 M edian (Min to 
Max) 
 Control vs. Crohn’s  Control vs. UC  Crohn’s vs. UC 
 Age  11.4 (6.3 to 15.3)  14.2 (8.0 to 16.3)  13.0 (8.5 to 15.8)  13.0 (6.3 to 16.3)  0.192  0.525  0.550 
 Male:female  8:4  8:3  8:3  24:10  1.00 a  1.00 a  1.00 a 
 Height Z-score  0.1 (  −  0.4 to 2.1)   −  0.7 (  −  2.5 to 1.9)  0.5 (  −  1.7 to 2.8)  0.1 (  −  2.5 to 2.8)  0.073  0.644  0.301 
 Weight Z-score  1.1 (  −  0.7 to 2.3)   −  1.2 (  −  2.5 to 2.6)  0.1 (  −  1.6 to 1.8)  0.2 (  −  2.5 to 2.6)  0.011  0.033  0.128 
 BMI Z-score  1.1 (  −  0.7 to 2.2)   −  1.0 (  −  3.7 to 2.8)   −  0.6 (  −  2.2 to 1.7)  0.2 (  −  3.7 to 2.8)  0.004  0.033  0.550 
 Symptom 
duration 
(months) 
 12 (0 b to 36)  6 (3 to 21)  5 (0.5 to 36)  7 (0 to 36)  0.064  0.089  0.449 
 BMI, body mass index; UC, ulcerative colitis. 
 P  <  0.05 indicated by bold font. 
 a Fisher’s exact test. 
 b Single asymptomatic patient undergoing colonoscopy for genetic risk of familial adenomatous polyposis coli. Next shortest symptom duration is 5 months. 
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 Bacterial diversity was signifi cantly reduced in CD when com-
pared with controls by three distinct indices (Shannon, Simpson, 
and Phylogenetic Diversity). No signifi cant diff erence in bacterial 
diversity was noted between UC and controls by any of the fi ve 
indices tested ( Table 3 ). 
 Phylum-level diversity comparisons revealed no statistically 
signifi cant diff erences for the three prevalent bacterial phyla of 
Bacteroidetes, Firmicutes, and Proteobacteria ( P  =  0.142 – 0.850, 
ANOVA;  Figure 1a – c ;  Table 4 ) and a signifi cant result only in 
the numerically small phylum Actinobacteria between CD and 
controls ( Table 4 ). Individual subject phylum-level diversity 
showed some variability, particularly within Proteobacteria in UC 
( Figure 1d ). Interestingly, a greater proportion of IBD reads were 
unmatched at phylum level, although these did not reach signifi -
cance. Diversity comparisons by RT-PCR also revealed no statistically 
signifi cant diff erences for  Bacteroidetes , Clostridial Cluster XIVa 
or  Enterobacteriaceae ( P  =  0.215 – 0.619, ANOVA;  Table 4 ), but did 
demonstrate a signifi cant increase in Clostridial Cluster IV in CD 
vs. controls ( P  =  0.029). 
 An additional ANOVA comparison was made between each 
of the three pairings (CD vs. Controls, UC vs. controls, and 
CD vs. UC) against the top 99.9 % of genus-level matches (78 
genera). Of a possible 234 comparisons, only 7 achieved statis-
tical significance. These were  Faecalibacterium , CD>Controls 
(mean 1,841.1 ( ± 1,004.6) vs. 921.7 ( ± 794.8) reads,  P  =  0.023); 
 Parabacteroides , Control>UC (mean 406.0 ( ± 427.9) vs. 113.6 
( ± 87.8) reads,  P  =  0.038);  Roseburia , UC>CD (mean 159.2 
( ± 171.2) vs. 37.0 ( ± 30.0) reads,  P  =  0.030);  Burkholderiales 
( / Other / Other), Control>UC (mean 53.3 ( ± 58.2) vs. 5.1 ( ± 8.1) 
reads,  P  =  0.013);  Prevotellaceae ( / Other), UC>CD (mean 21.8 
( ± 25.5) vs. 2.7 ( ± 3.7) reads,  P  =  0.023);  Desulfovibrio , UC>CD 
(mean 21.5 ( ± 25.3) vs. 2.7 ( ± 3.1),  P  =  0.024); and  Coriobac-
teriaceae , Control>CD (mean 15.7 ( ± 16.9) vs. 2.7 ( ± 2.9), 
 P  =  0.021). 
 Th e  Faecalibacterium fi nding (1,841.1 reads (16.7 % of all reads) 
from CD vs. 1,004.6 reads (8.4 % of all reads) from controls, 
 P  =  0.02) was replicated with  F. prausnitzii -specifi c RT-PCR (cor-
related with a 0.01 signifi cance level with pyrosequencing data 
with a Pearson coeffi  cient of 0.894,  n  =  33), which revealed mean 
prevalence of 36.0 ( ± 18.1) % of all bacteria in CD vs. 19.0 ( ± 14.1) % 
in controls ( P  =  0.02). Prevalence in UC was similar to controls by 
both methods (pyrosequencing from ANOVA: 10.1 ( ± 11.9) % of 
UC reads vs. 8.4 ( ± 7.2) % of controls,  F  =  0.187,  P  =  0.7; RT-PCR 
by  t -test: 25.5 ( ± 26.7) % of UC reads vs. 19.0 ( ± 14.1) % of controls, 
 P  =  0.5) ( Figure 2 ). Th e diff erence between CD and UC did not 
reach statistical signifi cance by either method (pyrosequencing 
 P  =  0.16, RT-PCR  P  =  0.3). 
 To explore clustering within disease categories, principal com-
ponents analysis (PCA) was undertaken on weighted Unifrac 
distances ( Figure 3 ). Interestingly, no distinct group clustering 
was observed within any phenotypic group. Although microbial 
diversity was signifi cantly reduced in CD, this was not refl ected by 
distinct clustering of CD subjects on PCA. 
 Table 3 .  Indices of bacterial  α -diversity from pyrosequencing data 
  Control  Crohn’s  UC  Statistical comparison by  t -test 
  Mean ( ± standard deviation)  Control vs. Crohn’s  Control vs. UC  Crohn’s vs. UC 
 Shannon  5.59 ( ± 0.30)  5.15 ( ± 0.46)  5.54 ( ± 0.64)  0.017  0.835  0.119 
 Simpson  0.96 ( ± 0.01)  0.93 ( ± 0.04)  0.94 ( ± 0.04)  0.042  0.227  0.429 
 Chao 1  448.6 ( ± 103.2)  428.0 ( ± 194.4)  552.0 ( ± 286.5)  0.758  0.279  0.251 
 Observed species  273.9 ( ± 42.7)  275.7 ( ± 79.7)  317.3 ( ± 124.6)  0.947  0.294  0.365 
 Phylogenetic diversity  24.5 ( ± 7.9)  17.0 ( ± 4.6)  24.0 ( ± 7.7)  0.012  0.882  0.019 
 UC, ulcerative colitis. 
 P  <  0.05 indicated by bold font. 
 Table 2 .  Real-time PCR primers used in this study 
 Target group  Primer name  Primer sequence  Reference 
 All bacteria  UniF  GTGSTGCAYGGY
YGTCGTCA 
 Ramirez-Farias 
 et al. ( 22 ) 
  UniR  ACGTCRTCCMCN
CCTTCCTC 
 
 Bacteroidetes  Bac303F  GAAGGTCCCCC
ACATTG 
 
  Bfr-Fmrev  CGCKACTTGGC
TGGTTCAG 
 
 Clostridial 
cluster XIVa 
 Erec482F  CGGTACCTGA
CTAAGAAGC 
 
  Erec870R  AGTTTYATTCT
TGCGAACG 
 
 Clostridial 
cluster IV 
 Clep866mF  TTAACACAATAAG
TWATCCACCTGG 
 
  Clept1240mR  ACCTTCCTCCG
TTTTGTCAAC 
 
 Faecalibacteri-
um prausnitzii 
 FPR-2F  GGAGGAAGAA
GGTCTTCGG 
 
  Fprau645R  AATTCCGCCTA
CCTCTGCACT 
 
 Enterobacte-
riaceae a 
 Enterobact
Dmod2F 
 GACCTCGCG
AGAGCA 
 Walker  et al.  (47) , 
modifi ed 
  Enter1432mod  CCTACTTCTTT
TGCAACCCA 
 Sghir  et al. ( 48 ), 
modifi ed 
 a Amplifi cation conditions as described in Ramirez-Farias  et al.  (22) , with primer 
annealing temperature of 63  ° C and extension at 72  ° C for 30  s. 
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both the CD and UC samples were obtained from infl amed tissue; 
hence, the reduction is not simply an artifact of infl ammation. 
Interestingly, a similar reduction in bacterial diversity has recently 
been noted in the oral microbiota of children with CD, but not in 
those with UC or healthy children ( 24 ). Adult studies examining 
biopsies from both active and quiescent UC suggest a reduction 
in bacterial diversity in the former ( 25,26 ). Our UC cohort have 
active infl ammation and are untreated, suggesting that the causa-
tive agent of a reduction in bacterial diversity is perhaps more 
complex than simply the presence of infl ammation. 
 PCA, a useful method of comparing diversity between individu-
als and looking for disease-specifi c microbial clustering, showed 
no clear distinctions between each of the three phenotypes we have 
studied (controls, CD, and UC). Th e landmark paper by Frank  et al. 
( 27 ) utilizing PCA in adult IBD biopsies outlined nominal sample 
clusters between an IBD subset and a control subset, neverthe-
less the phenotypic distinction on PCA was not absolute. Others 
 DISCUSSION 
 Our data describe a previously unexplored epoch in IBD micro-
biology, namely the onset of disease in treatment na ï ve children. 
A single adult study at IBD onset noted a signifi cant diff erence in 
unclassifi ed Bacteroidetes between CD and both UC and control 
patients, but no other signifi cant phylum changes when intesti-
nal biopsies were examined by denaturing gradient gel electro-
phoresis and clone libraries ( 23 ). Our study remains unique in 
the IBD literature by addressing the mucosal microbiota at the 
onset of disease in a population of treatment na ï ve children utiliz-
ing a deep sequencing approach, corroborated by RT-PCR. Our 
data challenge the view that phylum-level changes are impor-
tant in IBD etiology, cast doubt on the notion that a reduction 
in bacterial diversity occurs in UC, but fi rmly support this same 
hypothesis in CD, thus demonstrating an important microbial 
distinction between these two conditions. Our bacterial diversity 
results probably indicate a true reduction associated with CD, as 
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 Figure 1 .  Phylum-level diversity assessment. ( a – c ) Pie charts comprised all patient rarefi ed reads (11,000 reads per patient) to represent overall diversity 
of each cohort; phyla comprising   <  1 % have been removed for clarity. ( a ) Normal colon controls comprising 12 patients. ( b ) Crohn ’ s disease comprising 
11 patients. ( c ) Ulcerative colitis (UC) comprising 11 patients. ( d ) Individual patient diversity at phylum level as stacked bars. Individual patient data are 
presented in  Supplementary Table 1 . Spirochetes were identifi ed in a single Control patient (BISCUIT number 45) and were not noted on histopathol-
ogy. No Bacteroidetes were identifi ed in a single UC patient (BISCUIT number 25). BISCUIT, Bacteria in Infl ammatory bowel disease in Scottish Children 
Undergoing Investigation before Treatment. 
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such as Walker  et al. ( 28 ) have shown clear distinctions between 
disease phenotype using similar methods. Th e lack of diff erentia-
tion we have shown suggests evolution as disease enters chronicity, 
or perhaps that such diff erentiation is merely an artifact of 
disease-specifi c treatment strategies. 
 We propose that the current literature on IBD microbiology 
more accurately refl ects changes associated with disease chronic-
ity, and as such should not be extrapolated to the onset of disease. 
Furthermore, the important issue of active treatment, which is 
problematic when studying established disease, adds an important 
confounder which is underemphasized in the published literature. 
 In our study, all subjects received stimulant bowel preparation 
before colonoscopy. Th is may have altered the microbial profi le of 
the colonic mucosa, however since the treatment was given to all, 
this would likely act equivalently between groups. Furthermore, 
the organisms least likely to be aff ected would be those with adher-
ent properties, of most interest in the mucosal disease of IBD. In 
support of our approach, other investigators have demonstrated 
diff erences in the IBD microbiota despite prior bowel preparation 
( 10,29 ). Finally, a study design where children undergo diagnostic 
colonoscopy under general anesthetic without adequate prepara-
tion would be ethically unacceptable. Related to this latter point, 
the controls in this study were children undergoing colonoscopy 
to investigate gastrointestinal symptoms. Th ey were not therefore 
strictly  “ healthy ” controls; however, we have tried to address this 
by selecting only those with a macroscopically and microscopically 
normal colon for inclusion. 
 Although genetically similar ( 30 ), there are important distinc-
tions between adult and pediatric IBD with the latter being char-
acterized by a more extensive phenotype ( 31 ) and, at least in the 
case of CD, by a distinct immunophenotype ( 32 ). Environmental 
factors such as gastrointestinal microbial colonization may be etio-
logical factors of relevance to this distinction; hence, it is entirely 
possible that pediatric IBD is defi ned by a unique microbial signa-
ture, distinct from the adult disease. 
 Irrespective of the lack of phylum-level changes seen in our 
results at diagnosis, it appears that fecal microbial changes can be 
used as a useful biomarker for disease progression in children with 
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 Figure 2 .  Comparison of mean prevalence ( ± standard deviation) of  Fae-
calibacterium genus by pyrosequencing and  Faecalibacterium prausnitzii 
by real-time PCR against all bacteria in the distal colon of children with a 
normal colon, Crohn ’ s disease, and ulcerative colitis. 
 Table 4 .  Phylum-level statistical comparisons for pyrosequencing data against equivalent RT-PCR 
     Statistical Comparison by ANOVA 
  Control  Crohn’s  UC  Control vs. Crohn’s  Control vs. UC  Crohn’s vs. UC 
 Pyrosequencing  Mean percentage of 11,000 reads ( ± standard deviation)  F  P  F  P  F  P 
 Actinobacteria  0.5 ( ± 0.4)  0.2 ( ± 0.1)  0.4 ( ± 0.3)  4.371  0.049  0.258  0.617  3.516  0.075 
 Bacteroidetes  41.4 ( ± 17.0)  34.9 ( ± 11.0)  30.5 ( ± 17.1)  1.176  0.291  2.333  0.142  0.500  0.488 
 Firmicutes  42.5 ( ± 15.3)  45.3 ( ± 14.6)  43.8 ( ± 16.2)  0.198  0.661  0.037  0.850  0.053  0.820 
 Fusobacteria  0.1 ( ± 0.2)  0.1 ( ± 0.1)  0.5 ( ± 1.1)  0.003  0.956  1.629  0.216  1.524  0.231 
 Proteobacteria  6.1 ( ± 4.4)  4.9 ( ± 2.1)  10.1 ( ± 10.7)  0.616  0.441  1.480  0.237  2.545  0.126 
 Verrucomicrobia  0.3 ( ± 1.0)  0.3 ( ± 1.1)  0.2 ( ± 0.6)  0.001  0.973  0.077  0.784  0.084  0.775 
 “ Other ”  7.3 ( ± 7.2)  14.3 ( ± 12.3)  14.4 ( ± 17.7)  2.832  0.107  1.656  0.212  0.000  0.984 
 RT-PCR  Mean percentage of all bacteria ( ± standard deviation)       
 Bacteroidetes  39.4 ( ± 19.5)  30.9 ( ± 10.7)  27.7 ( ± 7.0)  1.632  0.215  2.898  0.105  0.575  0.458 
 Clostridial cluster IV  22.2 ( ± 15.7)  37.6 ( ± 15.8)  26.6 ( ± 25.7)  5.494  0.029  0.241  0.629  1.431  0.244 
 Clostridial cluster XIVa  22.9 ( ± 13.5)  28.3 ( ± 9.7)  22.3 ( ± 13.1)  1.200  0.286  0.011  0.919  1.443  0.246 
 Enterobacteriaceae  3.3 ( ± 1.5)  2.8 ( ± 1.8)  5.8 ( ± 4.2)  0.277  0.609  1.918  0.193  3.040  0.107 
 UC, ulcerative colitis. 
 P  <  0.05 indicated by bold font. 
 Six ANOVA analyses were performed comprising each of the three possible pairings (control vs. Crohn’s; control vs. UC; Crohn’s vs. UC) and both methodologies (pyrose-
quencing and RT-PCR). 
© 2012 by the American College of Gastroenterology The American Journal of GASTROENTEROLOGY
1919
 P
E
D
IA
T
R
IC
S 
 Microbiota of Pediatric IBD by Pyrosequencing 
than on gastrointestinal colonization  per se . Two explanations 
might be increased gastrointestinal transit (diarrhea) and anorexia 
in active UC. Understanding the impact of such infl uences and 
separating them from true etiological factors is a signifi cant chal-
lenge in gastrointestinal community microbiology. 
 Perhaps of most interest, we demonstrated a signifi cant increase 
in  F. prausnitzii in CD at diagnosis, in marked contrast with previ-
ous reports of a reduction in the species in adult CD ( 29,34,35 ). 
 F. prausnitzii is likely to have an important role in CD; how-
ever, its role may be more complex than our current under-
standing. It is clear from the seminal study of Sokol  et al. ( 34 ) 
that this single species is positively associated with an improved 
UC ( 33 ). Th e study of Michail  et al. ( 33 ) demonstrated alterations 
in the fecal microbiota of pediatric UC vs. healthy controls, but 
also showed that UC non-responders to steroid treatment dem-
onstrated fewer phylotypes within their fecal samples compared 
with responders when examined by microarray. Th is study raises 
an interesting consideration regarding microbial fi ndings in IBD, 
since the alterations seen could refl ect either causation or proxy 
association; nevertheless, their clinical utility as a biomarker may 
be suffi  cient alone to warrant their further exploration. Our own 
UC results were surprisingly similar to our normal colon control 
group, suggesting that the UC-specifi c fecal alterations described 
by Michail  et al. may refl ect an infl uence on the fecal stream rather 
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 Figure 3 .  Principal components analysis (PCA) of weighted Unifrac distances for denoised, chimera-checked pyrosequencing data with 97 % (top) and 
95 % (bottom) OTU clustering demonstrating PCA 1 vs. PCA 2 for normal colon controls, Crohn ’ s disease, and ulcerative colitis. No distinct clustering is 
seen within phenotypic groups. 
The American Journal of GASTROENTEROLOGY VOLUME 107 | DECEMBER 2012   www.amjgastro.com
1920
 P
E
D
IA
T
R
IC
S 
 Hansen  et al. 
outcome in established adult CD, with the demonstration that 
reduction in the proportion of this bacterium in intestinal 
samples was associated with endoscopic recurrence of disease. 
Th e same paper demonstrated the anti-infl ammatory properties 
of the bacterium in both a human  in vitro cell model and a murine 
 in vivo colitis model ( 34 ). Th e inference of course is that the 
reduction of  F. prausnitzii in CD is not simply a proxy for wors-
ening infl ammation / disease, but that the organism is an integral 
component of the anti-infl ammatory balance in health and its 
reduction may directly contribute to promotion of the disease 
state. Our data directly contradict this hypothesis. One possible 
explanation might be highlighted by  Bacteroides fragilis , an organ-
ism found to be capable of initiating colitis in animal models ( 36 ), 
but also of directing an anti-infl ammatory immune response 
( 37,38 ). Individual components of the microbiota may thus fulfi ll 
diff ering roles under diff erent conditions. Whether the increase 
in  F. prausnitzii seen in CD within our study represents a hitherto 
undescribed pro-infl ammatory role for the species, whether the 
early host / microbiota response to IBD induces proliferation of 
 F. prausnitzii in an attempt to reverse the infl ammatory change 
or whether the changes seen here are a proxy for some other 
phenomenon remains to be explained. 
 A single study from Jia  et al. ( 39 ) reported a correlation between 
clinical improvement and a reduction in fecal  F. prausnitzii abun-
dance in patients with CD who responded to enteral nutrition 
therapy. Th e authors explained their surprising  F. prausnitzii 
observation by commenting that it may merely be an innocent 
bystander in CD. Our data using more robust methodology are the 
fi rst to demonstrate an increase in this bacterium at CD diagnosis, 
which suggests a more complex and integral role for  F. prausnitzii 
in CD pathogenesis. Interestingly, the data of Willing  et al. ( 29 ), 
derived from pyrosequencing of fecal samples in established dis-
ease, demonstrated an increase in  Faecalibacterium in colonic, but 
a reduction in ileal CD although the former was not elaborated 
fully on within the paper. 
 Enteral nutrition is widely used in the management of pediatric 
CD, achieving high rates of remission in all phenotypes ( 40 ). Its mode 
of action remains to be explained fully, although published studies to 
date suggest that changes in the microbiota parallel clinical response 
( 41 ). A recent study demonstrated a reduction in fecal  F. prausnitzii 
in healthy adults fed a low fi ber enteral feed ( 42 ). Considering this 
paper in tandem with our results, one could hypothesize that enteral 
nutrition results in a temporary reduction of bacterial load, especially 
 F. prausnitzii whose growth is known to be stimulated by acetate pro-
duced by other bacteria, as well as by substrates supplied from a nor-
mal balanced diet. Th is could in turn lead to a temporary remission 
from CD activity. Th is hypothesis would fi t with the transient nature 
of enteral nutrition-induced remission in pediatric CD, with 60 – 70 % 
of patients relapsing within 12 months of cessation ( 43 ). 
 Another possible mechanism is suggested by very recent evi-
dence that  F. prausnitzii , although hitherto regarded as a strict 
anaerobe, has the ability to use low concentrations of oxygen as 
an electron acceptor through extracellular electron transfer ( 44 ). 
It is proposed that this ability may equip  F. prausnitzii for survival 
at the interface between oxygenated and anaerobic zones close to 
the colonic wall, which appears consistent with the high repre-
sentation of  F. prausnitzii noted here in biopsy samples. Distur-
bance to the colonic mucosa and mucus layer in disease states 
is likely to aff ect local oxygen gradients, with consequences for 
 F. prausnitzii populations. 
 Our study has generated novel and intriguing data especially 
with regard to  F. prausnitzii however larger prospective follow-
up studies, with serial sampling of the mucosal microbiota at 
diagnosis and at opportunistic times throughout treatment, 
would further improve our understanding of the microbiology 
of these chronic diseases. Such studies would lend important 
insight into longitudinal microbial changes and their relation-
ship with the potential confounders outlined above, hopefully 
helping to explain the complexities of the IBD microbiota and 
important organisms such as  F. prausnitzii , with direct implica-
tions for disease treatment. Th e recent publication of data from 
the Human Microbiome Project has clearly shown the abun-
dance, diversity and physiological importance of our microbial 
cohabitants and provided scaff olding for future studies ( 45,46 ). 
A greater understanding of the microbial pathogenesis of IBD is 
now within our grasp. 
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 Study Highlights 
 WHAT IS CURRENT KNOWLEDGE  
 3 The intestinal microbiota is considered as pivotal in 
infl ammatory bowel disease (IBD) pathogenesis. 
 3 Established adult IBD is associated with microbial changes 
and a reduction in bacterial diversity. 
 3 Faecalibacterium prausnitzii appears to have a protective 
role in established adult Crohn ’ s disease.  
 WHAT IS NEW HERE  
 3 Phylum-level bacterial changes are not important in 
pediatric infl ammatory bowel disease (IBD) at diagnosis. 
 3 Bacterial diversity is reduced in  de-novo pediatric Crohn ’ s 
disease but not in ulcerative colitis. 
 3 Faecalibacterium prausnitzii is increased in the colonic 
mucosa of newly diagnosed Crohn ’ s disease, suggesting a 
more complex role for the organism.  
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